0.4144

3.29% -0.0141

Heron Therapeutics Inc (HRTX)

Overview News Price History Option Chain Financials Why HRTX Down? Discussions Forecast Stock Split

Heron Therapeutics Inc stock is traded at $0.4144, with a volume of 2.68M. It is down -3.29% in the last 24 hours and up +1.47% over the past month. Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Previous Close:

$0.4285

Open:

$0.425

24h Volume:

2.68M

Relative Volume:

0.84

Market Cap:

$78.44M

Revenue:

$150.71M

Net Income/Loss:

$-30.94M

P/E Ratio:

-2.3452

EPS:

-0.1767

Net Cash Flow:

$-20.86M

1W Performance:

-5.47%

1M Performance:

+1.47%

6M Performance:

-70.19%

1Y Performance:

-81.33%

1-Day Range:

$0.4007

$0.4399

1-Week Range:

$0.4007

$0.4545

52-Week Range:

$0.382

$2.25

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name

Heron Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(858) 251-4400

Address

4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA

Employee

128

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

HRTX's Discussions on Twitter

Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRTX Heron Therapeutics Inc	0.4144	78.44M	150.71M	-30.94M	-20.86M	-0.1767
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-26	Downgrade	Needham	Buy → Hold
Jun-09-25	Initiated	H.C. Wainwright	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-23-24	Initiated	CapitalOne	Overweight
Mar-13-24	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Buy
Feb-20-20	Reiterated	Needham	Buy
Jan-16-19	Reiterated	Needham	Buy
Apr-05-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Reiterated	Mizuho	Buy
Mar-01-18	Reiterated	Needham	Buy
Jan-03-18	Initiated	Leerink Partners	Outperform
Sep-27-17	Initiated	Northland Capital	Outperform
Feb-27-17	Initiated	Needham	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy
Sep-23-15	Reiterated	Leerink Partners	Outperform
Sep-02-15	Initiated	BofA/Merrill	Buy
Aug-03-15	Reiterated	Brean Capital	Buy
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform
Jun-19-15	Reiterated	Leerink Partners	Outperform
Aug-07-14	Initiated	Noble Financial	Buy

View All

Heron Therapeutics Inc Stock (HRTX) Latest News

Jul 11, 2026

Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision - Yahoo Finance

Jul 11, 2026

Jul 07, 2026

Heron Therapeutics updates investors on business progress as development pipeline remains the key va - ad-hoc-news.de

Jul 07, 2026

Jul 04, 2026

HRTXHeron Therapeutics Inc Options - Finviz

Jul 04, 2026

Jun 30, 2026

Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling? - Insider Monkey

Jun 30, 2026

Jun 26, 2026